Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human FE 201836 single ascending dose study
NL-OMON43629Active, not recruiting
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jul 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of velmupressin in nocturia (4 arms), sponsored by Ferring Pharmaceuticals. Primary endpoints: Safety and tolerability of single intravenous and oral doses of FE 201836, Single oral dose pharmacokinetics of FE 201836 and 5 more. Started Jul 2015; status: active, not recruiting.
02
Drugs
velmupressin
03
Conditions
nocturia
Beyond the preview
Go deeper on NL-OMON43629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43629.